• Medscape InDiscussion: Lung Cancer

  • By: Medscape
  • Podcast

Medscape InDiscussion: Lung Cancer

By: Medscape
  • Summary

  • Listen to Medscape InDiscussion: Lung Cancer, a podcast series where thought leaders and clinical experts share their diverse insights and practical ideas for optimizing patient care. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/984257). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals.
    Copyright 2024, Medscape
    Show more Show less
activate_Holiday_promo_in_buybox_DT_T2
Episodes
  • S1 Episode 1: What Are the Risks and Benefits of Lung Cancer Screening?
    Aug 11 2022

    Drs Jacob Sands and Shawn Regis discuss the risks and benefits of lung cancer screening.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969532). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

    Resources

    National Lung Screening Trial https://www.cancer.gov/types/lung/research/nlst

    Lung Cancer: Screening, 1996 https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening-1996

    NELSON Lung Cancer Screening Study https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3266562/

    Early Lung Cancer Detection in High Risk Individuals (MILD) https://clinicaltrials.gov/ct2/show/NCT02837809

    Screening for Lung Cancer With Low-Dose Computed Tomography: An Evidence Review for the U.S. Preventive Services Task Force https://www.ncbi.nlm.nih.gov/books/NBK568573/

    Appendix A Table 5. Recommendations for Lung Cancer Screening With LDCT https://www.ncbi.nlm.nih.gov/books/NBK568579/table/appa.tab5/?report=objectonly

    ALA Press Release https://www.lung.org/media/press-releases/new-sbts-psa-1

    Lung CT Screening Reporting & Data System (Lung-RADS) https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/Lung-Rads

    Outcomes of Positive and Suspicious Findings in Clinical CT Lung Cancer Screening and the Road Ahead https://pubmed.ncbi.nlm.nih.gov/34818144/

    Lung Cancer Incidence and Mortality With Extended Follow-up in the National Lung Screening Trial https://www.jto.org/article/S1556-0864(19)30473-3/fulltext

    Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation https://www.jto.org/article/S1556-0864(20)30993-X/fulltext

    American Thoracic Society and American Lung Association Implementation Guide for Lung Cancer Screening https://www.lungcancerscreeningguide.org/

    Rescue Lung Society https://rescuelung.org/

    Lung Cancer Screening Resources https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/saved-by-the-scan/resources

    Go2 Foundation for Lung Cancer https://go2foundation.org/

    Show more Show less
    25 mins
  • S1 Episode 2: Biomarkers and Targeted Therapies for Lung Cancer
    Aug 11 2022

    Drs Jacob Sands and Pasi Jänne discuss the effectiveness of biomarkers and targeted therapies for lung cancer.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969533). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

    Resources

    Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma https://www.nejm.org/doi/full/10.1056/nejmoa0810699

    The Value of Next-Generation Sequencing in Patients With Non-Small Cell Lung Cancer https://www.medscape.org/viewarticle/975903

    ctDNA Shows Promise for Assessing Lung Cancer Treatment Response https://www.medscape.com/viewarticle/965587

    Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa2005653

    Structure-Based Classification Predicts Drug Response in EGFR-Mutant NSCLC https://www.nature.com/articles/s41586-021-03898-1

    Targeting Uncommon EGFR Mutations in Advanced NSCLC https://reference.medscape.com/recap/952720

    Afatinib Prescribing Information https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Gilotrif/Gilotrif.pdf?DMW_FORMAT=pdf

    Amivantamab Prescribing Information https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/RYBREVANT-pi.pdf

    Mobocertinib Prescribing Information https://content.takeda.com/?contenttype=pi&product=exkivity&language=eng&country=usa&documentnumber=1

    Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/10.1056/NEJMoa1713137

    Real-World Incidence and Impact of Pneumonitis in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors: a Multi-institutional Cohort Study https://jitc.bmj.com/content/10/6/e004670.long

    Show more Show less
    24 mins
  • S1 Episode 3: Immunotherapy and Lung Cancer Treatment
    Sep 15 2022

    Drs Jacob Sands and Jared Weiss discuss immunotherapy, including the importance of genomic testing, recent studies, new regimens, and the future of lung cancer treatment.

    Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969534). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US health care professionals.

    Resources

    Severe Immune-Related Adverse Events Are Common With Sequential PD-(L)1 Blockade and Osimertinib https://www.annalsofoncology.org/article/S0923-7534(19)31165-2/fulltext

    Pembrolizumab Versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1606774

    Pembrolizumab Versus Chemotherapy for Previously Untreated, PD-L1-Expressing, Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (KEYNOTE-042): A Randomised, Open-Label, Controlled, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32409-7/fulltext

    Cemiplimab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With PD-L1 of At Least 50%: A Multicentre, Open-Label, Global, Phase 3, Randomised, Controlled Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-67362100228-2/fulltext

    Cemiplimab-rwlc for First-Line Treatment of NSCLC With High PD-L1 Expression https://ascopost.com/issues/may-10-2021/cemiplimab-rwlc-for-first-line-treatment-of-nsclc-with-high-pd-l1-expression/

    Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1801005

    Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1810865

    Adjuvant Atezolizumab After Adjuvant Chemotherapy in Resected Stage IB-IIIA Non-Small-Cell Lung Cancer (IMpower010): A Randomised, Multicentre, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02098-5/fulltext

    Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC https://www.nejm.org/doi/10.1056/NEJMoa1716948

    IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC https://www.jto.org/article/S1556-0864(21)02322-4/fulltext

    First-Line Nivolumab plus Ipilimumab Combined With Two Cycles of Chemotherapy in Patients With Non-Small-Cell Lung Cancer (CheckMate 9LA): An International, Randomised, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30641-0/fulltext

    Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1910231

    FDA Approves Nivolumab plus Ipilimumab for First-Line mNSCLC (PD-L1 Tumor Expression ≥1%) https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1

    Clinical and Genomic Characteristics of Pts With Durable Benefit From Immune Checkpoint Inhibitors (ICI) in Advanced Non-Small Cell Lung Cancer (aNSCLC). https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.9048?af=R

    First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer https://www.nejm.org/doi/full/10.1056/nejmoa1809064

    Durvalumab plus Platinum–Etoposide Versus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (CASPIAN): A Randomised, Controlled, Open-Label, Phase 3 Trial https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32222-6/fulltext

    A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301) https://clinicaltrials.gov/ct2/show/NCT05060016

    Show more Show less
    30 mins

What listeners say about Medscape InDiscussion: Lung Cancer

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.